Standard Nivolumab Dosing
Nivolumab (Opdivo) uses fixed dosing for most indications, not weight-based adjustments. Adults typically receive 240 mg every 2 weeks or 480 mg every 4 weeks intravenously, regardless of body weight.[1][2]
When Is Weight-Based Dosing Used?
Weight-based dosing applies in specific cases, mainly for pediatric patients or certain combination therapies:
- For children (12+ years, ≥40 kg) with solid tumors, it's 240 mg/m² every 2 weeks or 480 mg/m² every 4 weeks, capped at adult fixed doses.[1]
- In combination with ipilimumab for melanoma or renal cell carcinoma, nivolumab is 1 mg/kg every 3 weeks (with ipilimumab 3 mg/kg), then transitions to fixed dosing after induction.[1][2]
No routine weight adjustments occur for adult monotherapy across approved uses like non-small cell lung cancer, melanoma, or renal cell carcinoma.[1]
Why Fixed Dosing Over Weight-Based?
Fixed dosing simplifies administration, reduces errors, and aligns with pharmacokinetics showing consistent exposure across adult weight ranges (45-120 kg). Studies like CheckMate trials supported this shift from earlier weight-based regimens to improve practicality without losing efficacy.[2][3]
Dose Adjustments for Other Factors
Adjust for toxicity, not weight:
- Hold or discontinue for severe immune-related adverse events (e.g., grade 3 colitis).[1]
- Renal/hepatic impairment: No changes needed.[1]
- Geriatrics: Fixed adult dose.[1]
What If Patient Weight Changes Significantly?
No formal guidance for re-dosing based on weight gain/loss in adults. Monitor clinically and follow toxicity rules. Consult oncology guidelines or the prescriber for outliers like obesity.[2]
[1]: Opdivo (nivolumab) Prescribing Information
[2]: FDA Label for Opdivo
[3]: CheckMate 067 Trial (NEJM)